Traverse Biotech II Inc.

New York, NY

UEI
JJUSGRQS7RM5
CAGE
Not on record
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
708 Greenwich St #4C, New York, NY 10014, USA
Website
traversebiotech.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Traverse Biotech II Inc.'s 3 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Development of a upar-targeting antibody-drug conjugate (ADC) for pancreatic adenocarcinoma - project summary traverse… Grant · R43CA309866 National Cancer Institute $399,896
Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis - project summary we are… Grant · R43AI181294 National Institute of Allergy and Infectious Diseases $596,655
CD3 bispecific for the treatment of ROR2-positive nsclc - project summary we are developing a novel CD3-bispecific… Grant · R43CA285040 National Cancer Institute $399,955

Quick answers

What is Traverse Biotech II Inc.'s UEI?

Traverse Biotech II Inc.'s Unique Entity ID (UEI) in SAM.gov is JJUSGRQS7RM5.

Where is Traverse Biotech II Inc. located?

Traverse Biotech II Inc.'s physical address in SAM.gov is 708 Greenwich St #4C, New York, NY 10014, USA.

Is Traverse Biotech II Inc. registered in SAM.gov?

Yes. Traverse Biotech II Inc.'s SAM.gov registration is active through October 31, 2026.

What is Traverse Biotech II Inc.'s most recent federal award?

Traverse Biotech II Inc.'s most recent federal grant award is Development of a upar-targeting antibody-drug conjugate (ADC) for pancreatic adenocarcinoma - project summary traverse… (R43CA309866), from National Cancer Institute, on September 1, 2026.

On GovTribe

See Traverse Biotech II Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login